News ReleasesPrinter friendly version
Protox Therapeutics conference call notification
Wednesday, March 8, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc.
(TSX-V: PRX) will hold an investor conference call to discuss the progress of
the company’s prostate cancer and benign prostatic hyperplasia (BPH) programs on
Monday, March 13th at 1:00p.m. PST (4:00p.m. EST). To participate on the call,
please dial 604-899-1159 or 1-888-458-1598 before 1:00 p.m. PST (access code
27319). A replay of the call will be available via the Internet at
www.protoxtherapeutics.com and also via telephone at 1-877-653-0545 (access
code 310769).
About Protox Therapeutics
Protox Therapeutics is a product-focused development-stage company and a leader
in advancing novel, targeted protein toxin therapeutics for treatment of cancer
and other diseases. The company’s PORxin™ platform is based on engineered
proaerolysin, a naturally-occurring pore-forming protoxin. Product candidates
generated using the PORxin™ platform are inactive prodrugs that are activated
at the tumor site into potent toxins by cancer specific proteases, thereby
causing cancer cell death. PRX302, the company’s lead product candidate for
localized prostate cancer and benign prostatic hyperplasia, is a first-in-class
pore-forming targeted toxin for cancer therapy.
Link to the webcast replay of the conference call Monday, March 13, 2006 at 1:00PM PST
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Tel: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
| 
